Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 18

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 18
---
 offering;                                                        |

| • |     | no exercise by the underwriters of their option to purchase additional shares of our common stock and no issuance                                                                                  
 of additional shares of common stock issuable in respect of anti-dilution adjustments to the Series C convertible preferred stock that may be made upon the underwriters’ exercise of such option. |

10

SUMMARY FINANCIAL INFORMATION The following tables set forth a summary of our financial data as of, and for the periods ended on, the dates indicated. We have derived the summary statements of operations data for the years ended December 31, 2024 and 2023 from our audited financial statements included elsewhere in this prospectus. The following summary condensed statements of operations data for the six months ended June 30, 2025 and 2024, and the summary condensed balance sheet data as of June 30, 2025 have been derived from our unaudited condensed financial statements included elsewhere in this prospectus. Our financial statements appearing elsewhere in this prospectus have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. Our unaudited condensed financial statements were prepared on a basis consistent with our audited consolidated financial statements and include, in our opinion, all adjustments of a normal and recurring nature that are necessary for the fair statement of the financial information set forth in those statements included elsewhere in this prospectus. Our historical results are not necessarily indicative of results that should be expected in any future period. You should read the following summary financial data together with our financial statements and related notes included elsewhere in this prospectus and in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

|                                                                                             |     | Year Ended                                     
 December 31,                                   
 2024                                           |           |   |     | 2023 |           |   |     | Six Months Ended 
 June 30,         
 2025             |           |   |     | 2024 |           |   |
|:--------------------------------------------------------------------------------------------|:----|:-----------------------------------------------|----------:|:--|:----|:-----|----------:|:--|:----|:-----------------|----------:|:--|:----|:-----|----------:|:--|
|                                                                                             |     | -in thousands, except share and per share data |           |   |     |      |           |   |     |                  |           |   |     |      |           |   |
| Statements of Operations Data